Immunology & Oncology
Actuate Therapeutics develops small molecule therapeutics for the treatment of cancer and fibrotic diseases. Actuate’s lead drug candidate is a first-in-class small molecule for the treatment of chemotherapeutic and radiation resistant cancers.
GSK3B-This enzyme is involved in signalling pathways responsible for regulating glucose levels, cell growth, and tissue healing. Over-activation of these critical pathways by GSK3B accumulation has been linked to a variety diseases, including cancers, type II diabetes, and inflammatory diseases. Actuate is investigating using novel small molecule inhibitors of GSK3B to down-regulate the activity of these signaling pathways. It has been hypothesized that targeting GSK3B may overcome chemotherapeutic resistance. Initial clinical trials of this therapeutic will focus on carcinomas (glioblastoma, pancreatic, breast, ovarian) with a plan to include fibrotic autoimmune diseases later on.
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Walz, A; Ugolkov, A; Chandra, S; Kozikowski, A; Carneiro, BA; O’Halloran, TV; Giles, FJ; Billadeau, DD; Mazar, AP. Clinical Cancer Research. 2017 Apr 15; 23(8): 1891-1897.
Targeting GSK-3: a promising approach for cancer therapy?
Ougolkov, AV; Biladeau, DD. Future Oncology. 2006 Feb; 2(1): 91-100.
Actuate is currently transitioning from preclinical proof of concept studies to clinical trials.
Cancers: Currently recruiting for a phase 1/2 trial in patients with refractory solid tumors and hematological malignancies
Fibrotic Diseases: Proof of concept (animal models)
- Small molecules
- Orphan diseases
- Chemotherapeutic resistance cancers
Actuate is interested in both industry and academic partnerships to license, purchase, or collaborate on the development of therapeutics for cancer and inflammatory diseases.